Health system cost of breast cancer treatment in Addis Ababa, Ethiopia.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
14
05
2022
accepted:
12
09
2022
entrez:
6
10
2022
pubmed:
7
10
2022
medline:
12
10
2022
Statut:
epublish
Résumé
Breast cancer is the leading cancer among women with an annual crude incidence of 27.4 per 100,000 in Ethiopia. The aims of this study were to (a) estimate the unit cost of breast cancer treatment for the standard Ethiopian patient, (b) identify the cost drivers, (c) project the total cost of breast cancer treatment for the next five years, and (d) estimate the economic burden of the disease in the main specialized tertiary hospital-Tikur Anbessa Specialized Hospital (TASH) Addis Ababa. Primary data were collected from health and non-health professionals. Secondary data were collected from patient`s charts and official reports from various national and international organisations including data from TASH. To establish work-time estimates, we asked professionals on their time usage. A total of US$ 33,261 was incurred to treat 52 Addis Ababa resident female breast cancer patients in TASH between July 2017 and June 2019. The unit cost of treatment for a hypothetical breast cancer patient to complete her treatment was US$ 536 for stage I and US$ 705 for stage II and III using the existing infrastructure. This cost increased to US$ 955 for stage I and US$ 1157 for stage II and III when infrastructure amortization was considered. The projected total costs of breast cancer treatment in TASH is between US$ 540,000 and US$ 1.48million. However, this will increase to US$ 870,000 and US$ 2.29 million when the existing fixed assets are changed. The economic burden of breast cancer treatment is high compared to the economic status of the country. Thus, it is recommended that TASH should revise its charges and breast cancer should be included in the Social and Community based health insurance scheme. JEL classification: H51, H75, I18, P46.
Sections du résumé
BACKGROUND
Breast cancer is the leading cancer among women with an annual crude incidence of 27.4 per 100,000 in Ethiopia. The aims of this study were to (a) estimate the unit cost of breast cancer treatment for the standard Ethiopian patient, (b) identify the cost drivers, (c) project the total cost of breast cancer treatment for the next five years, and (d) estimate the economic burden of the disease in the main specialized tertiary hospital-Tikur Anbessa Specialized Hospital (TASH) Addis Ababa.
METHODS
Primary data were collected from health and non-health professionals. Secondary data were collected from patient`s charts and official reports from various national and international organisations including data from TASH. To establish work-time estimates, we asked professionals on their time usage.
RESULT
A total of US$ 33,261 was incurred to treat 52 Addis Ababa resident female breast cancer patients in TASH between July 2017 and June 2019. The unit cost of treatment for a hypothetical breast cancer patient to complete her treatment was US$ 536 for stage I and US$ 705 for stage II and III using the existing infrastructure. This cost increased to US$ 955 for stage I and US$ 1157 for stage II and III when infrastructure amortization was considered. The projected total costs of breast cancer treatment in TASH is between US$ 540,000 and US$ 1.48million. However, this will increase to US$ 870,000 and US$ 2.29 million when the existing fixed assets are changed.
CONCLUSION
The economic burden of breast cancer treatment is high compared to the economic status of the country. Thus, it is recommended that TASH should revise its charges and breast cancer should be included in the Social and Community based health insurance scheme. JEL classification: H51, H75, I18, P46.
Identifiants
pubmed: 36201488
doi: 10.1371/journal.pone.0275171
pii: PONE-D-22-14104
pmc: PMC9536570
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0275171Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Glob Health Action. 2013 Feb 04;6:18872
pubmed: 23394855
PLoS One. 2013 Jul 23;8(7):e69728
pubmed: 23936088
Rev Lat Am Enfermagem. 2007 Sep-Oct;15 Spec No:786-91
pubmed: 17934586
Cancer Epidemiol. 2012 Jun;36(3):237-48
pubmed: 22459198
Cancer Epidemiol Biomarkers Prev. 2010 Aug;19(8):1893-907
pubmed: 20647400
PLoS One. 2019 Sep 19;14(9):e0219519
pubmed: 31536505
Cost Eff Resour Alloc. 2010 Sep 10;8:16
pubmed: 20828417
Int J Cancer. 2014 Aug 1;135(3):702-9
pubmed: 24375396
PLoS One. 2018 Nov 29;13(11):e0207928
pubmed: 30496219
S Afr Med J. 2020 Mar 30;110(4):296-301
pubmed: 32657741
World J Surg Oncol. 2018 Mar 22;16(1):63
pubmed: 29566711
Breast Care (Basel). 2013 Mar;8(1):29-33
pubmed: 24715840